Peptide Therapeutics In Metabolic Disorders Market
- 2026 年市場規模
- USD 39.3 Bn
- 2033 年預估規模
- USD 47.8 Bn
- 年複合成長率 CAGR
- 14.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
完整報告名稱與涵蓋範圍
Peptide Therapeutics In Metabolic Disorders Market, By Route Of Administration (Intravenous, Oral, Nasal, Others), By Synthesis Technology (Solid Phase Peptide Synthesis, Liquid Phase Peptide Synthesis, Hybrid Technology), By Distribution Channels (Hospitals, Specialty Clinics, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
The Peptide Therapeutics In Metabolic Disorders Market is anticipated to grow at a CAGR of 14.6% with USD 39.3 Bn in 2026 and is expected to reach USD 47.8 Bn in 2033. Peptide therapeutics play an increasingly important role in treating metabolic disorders such as diabetes, obesity, and related conditions. These therapies target biological pathways that regulate glucose levels, appetite, insulin activity, and energy metabolism. Rising disease prevalence and demand for effective long-term treatments encourage pharmaceutical companies to advance peptide-based therapies. Meanwhile, improvements in peptide engineering, drug delivery, and formulation technologies help developers enhance treatment performance and expand the use of peptide therapeutics in metabolic disease management.
Pharmaceutical companies are developing next-generation peptide therapies that improve treatment effectiveness, durability, and patient convenience. Incretin-based therapies, including GLP-1 and dual- or multi-receptor agonists, have expanded the use of peptide medicines in metabolic care. Researchers are also advancing oral delivery systems, extended-release formulations, combination therapies, and novel molecular targets. These innovations are broadening treatment options and driving investment in clinical development, manufacturing capacity, and advanced peptide-based therapeutic platforms.
Market Dynamics
The rising prevalence of diabetes, obesity, and other metabolic disorders continues to increase demand for effective treatments. Healthcare providers seek therapies that support durable disease management and improve patient outcomes. Peptide therapeutics target specific metabolic pathways and continue to gain clinical interest. Pharmaceutical companies are expanding research programs and developing innovative peptide-based therapies to address unmet treatment needs across diabetes, obesity, and related metabolic conditions.
Advances in peptide engineering, molecular design, drug delivery, and formulation technologies are improving therapeutic performance and patient convenience. Developers are creating longer-acting formulations, oral delivery systems, combination therapies, and multi-target molecules to enhance treatment outcomes. The success of incretin-based therapies has encouraged pharmaceutical companies to investigate additional biological targets and treatment combinations. These innovations are expanding peptide applications and attracting greater investment across the development pipeline.
Pharmaceutical companies face several challenges when developing and manufacturing peptide therapeutics. Complex molecular structures, stability requirements, specialized production processes, and strict quality-control standards can increase development complexity. Developers must conduct extensive clinical studies to establish long-term safety and efficacy. Alternative treatment options and patient adherence concerns also influence competition. Companies that improve drug delivery, manufacturing efficiency, treatment duration, and patient convenience can strengthen their position in metabolic disorder treatment.
Key Features of the Study
• This report provides an in-depth analysis of the Peptide Therapeutics in Metabolic Disorders Market and presents market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year.
• It highlights potential revenue opportunities across various market segments and provides attractive investment proposition matrices for stakeholders involved in the Peptide Therapeutics in Metabolic Disorders Market.
• This study offers key insights into market drivers, restraints, opportunities, emerging peptide technologies, drug delivery advancements, incretin-based therapies, therapeutic innovations, clinical development trends, regional outlook, and competitive strategies adopted by leading market participants.
• It profiles key players in the Peptide Therapeutics in Metabolic Disorders Market based on company overview, therapeutic portfolio, pipeline analysis, recent developments, clinical advancements, financial performance, and strategic initiatives.
• Key companies covered as part of this study include AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company, Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm Pharmaceuticals Inc., and Novo Nordisk A/S.
• Insights from this report enable pharmaceutical companies, biotechnology firms, healthcare providers, investors, researchers, and management teams to make informed decisions regarding drug development, peptide innovation, clinical research, manufacturing investments, market expansion, strategic collaborations, and therapeutic commercialization.
• The Peptide Therapeutics in Metabolic Disorders Market report serves a wide range of stakeholders, including investors, pharmaceutical companies, biotechnology companies, contract development and manufacturing organizations, healthcare providers, research institutions, technology developers, new market entrants, and financial analysts.
• Stakeholders can make well-informed strategic decisions through the analytical frameworks, competitive benchmarking, therapeutic pipeline assessment, treatment application analysis, regional evaluation, and market evaluation matrices presented in the Peptide Therapeutics in Metabolic Disorders Market report.
Market Segmentation
• By Route Of Administration (Revenue, USD Bn, 2021-2033)
o Intravenous
o Oral
o Nasal
o Others
• By Synthesis Technology (Revenue, USD Bn, 2021-2033)
o Solid Phase Peptide Synthesis
o Liquid Phase Peptide Synthesis
o Hybrid Technology
• By Distribution Channels (Revenue, USD Bn, 2021-2033)
o Hospitals
o Specialty Clinics
o Retail Pharmacy
o Online Pharmacy
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o AstraZeneca plc
o F. Hoffmann-La Roche Ltd
o Sanofi S.A.
o Teva Pharmaceutical Industries Ltd.
o PolyPeptide Group
o Eli Lilly and Company
o Bachem Holding AG
o Takeda Pharmaceuticals Co. Ltd.
o Ipsen S.A
o Rhythm Pharmaceuticals Inc.
o Novo Nordisk A/S.
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Route of Administration
Market Snapshot, By Synthesis Technology
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Peptide Therapeutics In Metabolic Disorders Market, By Route of Administration, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Intravenous
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Nasal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Global Peptide Therapeutics In Metabolic Disorders Market, By Synthesis Technology, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Solid Phase Peptide Synthesis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Liquid Phase Peptide Synthesis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Hybrid Technology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Global Peptide Therapeutics In Metabolic Disorders Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Global Peptide Therapeutics In Metabolic Disorders Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Synthesis Technology, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
AstraZeneca plc
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
F. Hoffmann-La Roche Ltd
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Sanofi S.A.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Teva Pharmaceutical Industries Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
PolyPeptide Group
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bachem Holding AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Takeda Pharmaceuticals Co. Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ipsen S.A
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Rhythm Pharmaceuticals Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novo Nordisk A/S.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們